Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 5Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 1057Stomach Neoplasms 802Carcinoma, Hepatocellular 785Pancreatic Neoplasms 577Rectal Neoplasms 449Colonic Neoplasms 405Esophageal Neoplasms 363Liver Neoplasms 225Esophageal Squamous Cell Carcinoma 144Neoplasms 134Cholangiocarcinoma 129Neoplasm Metastasis 117Breast Neoplasms 117Gastrointestinal Neoplasms 105Lung Neoplasms 76Biliary Tract Neoplasms 73Recurrence 61Prostatic Neoplasms 52Ovarian Neoplasms 49Barrett Esophagus 47Carcinoma, Non-Small-Cell Lung 44Anastomotic Leak 43Bile Duct Neoplasms 42Gastrointestinal Stromal Tumors 40Gallbladder Neoplasms 40Head and Neck Neoplasms 38Digestive System Neoplasms 35Anus Neoplasms 34Colonic Polyps 33Adenocarcinoma Of Esophagus 32

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Borderline Resectable Pancreatic Cancer × Gastrointestinal × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04855331 2023-05-09

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Fudan University

Phase NA Unknown
120 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04617821 2022-01-28

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Fudan University

Phase 3 Unknown
300 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡